The emerging zika virus epidemic in the Americas: Research priorities by Lazear, H.M. et al.
The Emerging Zika Virus Epidemic in the Americas
Research Priorities
On February 1, 2016, the World Health Organization
declared a “public health emergency of international
concern” regarding neurological disorders associated
with the rapid emergence of Zika virus (ZIKV) in the
Americas. Since being detected in Brazil in early 2015,
ZIKV has spread extensively, with most countries in
Latin America and the Caribbean now reporting local
transmission of the virus. An association between con-
genital ZIKV infection and birth defects, most promi-
nently microcephaly, has prompted intense concern
among health officials and the public.
The current ZIKV epidemic follows a trend that
started more than 500 years ago with introduction of the
yellow fever mosquito, Aedes aegypti, from Africa into the
Americas. The invasion of A aegypti led to epidemics of
old world arboviral diseases such as yellow fever (1647),
dengue fever (1780), dengue hemorrhagic fever (1982),
and chikungunya (2013), which share the same mos-
quito vector and urban transmission cycle as ZIKV. The
worldwide call for new initiatives to combat ZIKV must
be informed by decades of basic and applied research
on dengue and other closely related arboviruses. This
Viewpoint will focus on research priorities to better un-
derstand and effectively respond to the ZIKV crisis.
New Diseases From an Old Virus?
Zika virus is a flavivirus related to dengue, West Nile, and
yellow fever viruses.1,2 Sequence analyses show that
ZIKV isolates from South America are similar to those
from French Polynesia, suggesting that the virus was in-
troduced to Brazil by an infected traveler or mosquito
from the South Pacific. However, the virus sequences are
not identical, and there is even greater divergence from
historical African isolates. Much of this difference likely
represents random genetic drift, but even minor changes
to the viral genome could have a significant effect on hu-
man disease.
As an example, a single amino acid change in its sur-
face glycoprotein enables chikungunya virus to use
Aedes albopictus mosquitoes as a vector, facilitating epi-
demic spread into new areas. It is unknown whether spe-
cific changes in ZIKV (ie, new viral strains) are respon-
sible for the unexpected disease patterns in the current
pandemic. Cell culture, mosquito, and vertebrate ani-
mal models are needed to compare the replication,
pathogenesis, and transmission of historical and con-
temporary ZIKV strains. Molecular tools to map viral ge-
netic determinants that contribute to increased trans-
mission and disease also are needed.
Diagnostic Dilemmas
Currently available serological tests cannot reliably
distinguish ZIKV infection from other flaviviruses,
severely hampering studies of ZIKV spread and disease.
The public health response to this epidemic depends
on rapid development of accurate diagnostics. Most
flavivirus infections remain unrecognized or cause an
undifferentiated febrile illness, and therefore, surveil-
lance based on clinical criteria alone can be misleading.
In addition, because flavivirus infections cause acute
infections that are rapidly cleared by the human
immune response, detection of viral nucleic acid or
antigens in the peripheral blood is typically limited to
a narrow window of 1 to 5 days after the onset of
symptoms.3
Serology, a mainstay of viral surveillance and diag-
nosis, is confounded by extensive antibody cross-
reactivity between flaviviruses.3 The presence of
immunoglobulin G antibodies that bind to ZIKV could
result from past infection with any of several flavivi-
ruses or prior vaccination with a flavivirus vaccine.
This is not simply an academic scenario because ZIKV
is emerging in areas with transmission of all 4 dengue
serotypes, yellow fever vaccination, and dengue vac-
cines approved or in trials. In most metropolitan areas
in Latin America at risk of ZIKV transmission, dengue
seroprevalence in adults is likely to exceed 90%.4
Perhaps the most immediate research priority is
the development of simple serological diagnostic
assays for tracking the spread of ZIKV and for studying
links between ZIKV infection and severe clinical mani-
festations. Currently, an immunoglobulin M (IgM)
enzyme-linked immunosorbent assay is the only assay
that can be used to test whether an individual has
been recently exposed to ZIKV. However, the IgM
assay has poor specificity in people who have been
previously exposed to another flavivirus (ie, most
people living in high-risk areas of Latin America and
the Caribbean).
Although flavivirus cross-reactive antibodies domi-
nate the human immune response, exposed individu-
als develop antibodies that target unique epitopes for
each flavivirus, and such virus-specific antibodies are
linked to protection against dengue virus.5 Building on
approaches developed for dengue and West Nile vi-
ruses, the major ZIKV-specific epitopes targeted by hu-
man antibodies need to be defined and mapped to de-
velop more specific diagnostics.
Pathogenesis and Clinical Complications
Following a mosquito bite, keratinocytes and dendritic
cells in the skin are presumed to be the initial targets of
ZIKV infection. Viremia develops some 1 to 5 days later,
and the virus is cleared from circulation within 2 weeks
of infection. The cellular and tissue tropism of ZIKV in hu-
mans is not completely understood, and there is a need
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may not be reliably diagnosed until after 24 to 28 weeks of gesta-
tion and in some cases may not be evident until birth. The full spec-
trum of potential developmental defects caused by fetal ZIKV in-
fection is unknown, but other manifestations seem likely and may
aid in fetal diagnosis. The currently identified microcephaly cases may
represent the most severe effects of ZIKV infection, and many other
infants who were infected may have better outcomes.
Given the potential for an epidemic of developmental defects
due to congenital ZIKV infection, studies are needed to under-
stand the probability of transplacental transmission upon ZIKV in-
fection during pregnancy; the risk of transmission at different stages
of gestation; the spectrum of effects caused by congenital ZIKV in-
fection; and additional factors that may contribute to transplacen-
tal transmission and teratogenic potential of ZIKV. Evidence-based
recommendations regarding prenatal screening for ZIKV infection
and associated congenital abnormalities, including the roles of di-
agnostic procedures such as ultrasound and amniocentesis as well
as information about possible outcomes and options for interven-
tion, must be developed. In addition, the effect of prior flavivirus im-
munity (eg, from dengue virus infection or vaccination) on ZIKV
pathogenesis and disease severity must be understood.
Conclusions
The size of the current ZIKV epidemic, its potential for further
spread, and the potential teratogenic effects of this virus require
development of ZIKV-specific diagnostic agents and a better under-
standing of pathogenic mechanisms. The association between
ZIKV infection and microcephaly has been the cause of much alarm
and has been the driving force behind a substantial public health
response and a drive to develop vaccines and antivirals to combat
ZIKV infection.
Zika virus represents just the most recent example of an epi-
demic of vector-borne disease brought about by the introduction
of a virus to a new host population and ecological landscape. Al-
though current research priorities must focus on the immediate need
to develop specific diagnostic tools and understand the terato-
genic potential of ZIKV, public health efforts to address the current
epidemic must be informed by experience with previous out-
breaks of viruses transmitted by Aedes mosquitoes.
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for basic pathogenesis studies to understand the tropism, immune 
response, and pathogenic mechanisms of ZIKV.
Even though many questions remain surrounding transplacen-
tal transmission and teratogenic effects of ZIKV, accumulating evi-
dence strongly suggests a causal role in the development of birth 
defects. In addition to the timing and geographic distribution of mi-
crocephaly cases relative to ZIKV infections, studies of infants and 
fetuses with microcephaly have detected ZIKV RNA in placenta, am-
niotic fluid, and fetal tissues; viral particles, antigen, and complete 
viral genome in brain tissue; and ZIKV IgM in amniotic fluids.6 A re-
cent report also documented severe ocular abnormalities involv-
ing the macula and optic disc among infants with microcephaly born 
in Brazil after a regional ZIKV outbreak.7
Many viruses acquired in pregnancy have different fetal trans-
mission rates by trimester in which a pregnant woman is infected. 
Viruses tend to be more easily transmitted at later gestational ages, 
but have more severe effects on the fetus if transmitted earlier in 
pregnancy. Conversely, the risk of cytomegalovirus sequelae in in-
fants may be as low as 6% with second trimester infection, and there 
appears to be an extremely low to no risk during the third trimester.8
The overall perinatal transmission rate of ZIKV, with resultant 
fetal infection, is not known, nor is it known whether vertical trans-
mission rates differ by gestational age at the time of exposure or se-
verity of maternal infection. Furthermore, among fetuses infected 
with ZIKV, the rate that newborns are significantly affected at birth 
is unknown, as well as whether the virus can be transmitted during 
labor and delivery or through breastfeeding.
The amniotic fluid of a fetus infected with cytomegalovirus does 
not become positive by polymerase chain reaction until at least 
7 weeks after transmission. Because the sensitivity of cytomegalo-
virus polymerase chain reaction is lower during the initial 21 ges-
tational weeks, amniocentesis is usually performed after 21 gesta-
tional weeks for a suspected infection, unless the fetus already shows 
sonographic signs of infection. This is likely to be true for ZIKV, but 
remains unknown. Zika virus seems to have a tropism for fetal brain 
tissue, but the entire spectrum of clinical findings for congenital ZIKV 
infection has not been adequately characterized.
Many ultrasonographic findings of fetal viral infections can be 
identified as early as 18 to 20 gestational weeks, but microcephaly
